© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 1, 31-38,
January 3, 2001
© 2001 Oxford University Press
Granulocyte Colony-Stimulating Factor in the Treatment of High-Risk Febrile Neutropenia: a Multicenter Randomized Trial
Affiliations of authors: R. García-Carbonero, M. V. Tornamira, A. Arcediano, C. Gómez, J. L. Pérez-Gracia, J. Hornedo, H. Cortés-Funes, L. Paz-Ares, Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain; J. I. Mayordomo, A. Yubero, A. Trés, Division of Medical Oncology, Hospital Clínico, Zaragoza, Spain; M. López-Brea, F. Rivera, Division of Medical Oncology, Hospital M. Valdecilla, Santander, Spain; A. Rueda, Division of Medical Oncology, Hospital Clinico, Malaga, Spain; V. Guillem, Division of Medical Oncology, Instituto Valenciano de Oncologia, Valencia, Spain; C. Lumbreras, Division of Infectious Diseases, Hospital Universitario Doce de Octubre, Madrid.
Correspondence to: Luis Paz-Ares, M.D., Servicio de Oncologia Medica, Hospital Universitario Doce de Octubre, Avenida de Cordoba Km 5,4, Madrid 28041, Spain (e-mail: lpaz{at}hdoc.insalud.es).
Background: Granulocyte colony-stimulating factors (G-CSFs) have been shown to help prevent febrile neutropenia in certain subgroups of cancer patients undergoing chemotherapy, but their role in treating febrile neutropenia is controversial. The purpose of our study was to evaluate—in a prospective multicenter randomized clinical trial—the efficacy of adding G-CSF to broad-spectrum antibiotic treatment of patients with solid tumors and high-risk febrile neutropenia. Methods: A total of 210 patients with solid tumors treated with conventional-dose chemotherapy who presented with fever and grade IV neutropenia were considered to be eligible for the trial. They met at least one of the following high-risk criteria: profound neutropenia (absolute neutrophil count <100/mm3), short latency from previous chemotherapy cycle (<10 days), sepsis or clinically documented infection at presentation, severe comorbidity, performance status of 3–4 (Eastern Cooperative Oncology Group scale), or prior inpatient status. Eligible patients were randomly assigned to receive the antibiotics ceftazidime and amikacin, with or without G-CSF (5 µg/kg per day). The primary study end point was the duration of hospitalization. All P values were two-sided. Results: Patients randomly assigned to receive G-CSF had a significantly shorter duration of grade IV neutropenia (median, 2 days versus 3 days; P = .0004), antibiotic therapy (median, 5 days versus 6 days; P = .013), and hospital stay (median, 5 days versus 7 days; P = .015) than patients in the control arm. The incidence of serious medical complications not present at the initial clinical evaluation was 10% in the G-CSF group and 17% in the control group (P = .12), including five deaths in each study arm. The median cost of hospital stay and the median overall cost per patient admission were reduced by 17% (P = .01) and by 11% (P = .07), respectively, in the G-CSF arm compared with the control arm. Conclusions: Adding G-CSF to antibiotic therapy shortens the duration of neutropenia, reduces the duration of antibiotic therapy and hospitalization, and decreases hospital costs in patients with high-risk febrile neutropenia.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Shochat and V. Rom-Kedar Novel Strategies for Granulocyte Colony-Stimulating Factor Treatment of Severe Prolonged Neutropenia Suggested by Mathematical Modeling Clin. Cancer Res., October 15, 2008; 14(20): 6354 - 6363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ziepert, R. Schmits, L. Trumper, M. Pfreundschuh, M. Loeffler, and On behalf of the German High-Grade Non-Hodgkin's L Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma Ann. Onc., April 1, 2008; 19(4): 752 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. L. Du, D. R. Lairson, C. E. Begley, and S. Fang Temporal and Geographic Variation in the Use of Hematopoietic Growth Factors in Older Women Receiving Breast Cancer Chemotherapy: Findings From a Large Population-Based Cohort J. Clin. Oncol., December 1, 2005; 23(34): 8620 - 8628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. A.C. Clark, G. H. Lyman, A. A. Castro, L. G.O. Clark, and B. Djulbegovic Colony-Stimulating Factors for Chemotherapy-Induced Febrile Neutropenia: A Meta-Analysis of Randomized Controlled Trials J. Clin. Oncol., June 20, 2005; 23(18): 4198 - 4214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L Stanford, S. D Zondor, and E. Cobos Is pegfilgrastim appropriate for the treatment of established febrile neutropenia? Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 113 - 119. [Abstract] [PDF]
|
|